Company profile

Ticker
ALLO
Exchange
CEO
David D. Chang
Employees
Incorporated
Location
Fiscal year end
SEC CIK

ALLO stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 20
24 Sep 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
21 Sep 20 Schmidt Eric Thomas Common Stock Sell Dispose S Yes 37.04 1,911 70.78K 1,212,595
21 Sep 20 Schmidt Eric Thomas Common Stock Sell Dispose S Yes 35.9591 3,200 115.07K 1,214,506
21 Sep 20 Schmidt Eric Thomas Common Stock Sell Dispose S Yes 34.755 9,889 343.69K 1,217,706
1 Sep 20 Veer Bhavnagri Common Stock Sell Dispose S Yes 35.89 400 14.36K 353,902
1 Sep 20 Veer Bhavnagri Common Stock Sell Dispose S Yes 35.35 24,600 869.61K 354,302
1 Sep 20 Veer Bhavnagri Common Stock Option exercise Aquire M No 2.27 25,000 56.75K 378,902
1 Sep 20 Veer Bhavnagri Stock Option Common Stock Option exercise Dispose M No 2.27 25,000 56.75K 248,800
13 Aug 20 Moore Alison Common Stock Option exercise Aquire M No 2.27 32,451 73.66K 126,272
13 Aug 20 Moore Alison Stock Option Common Stock Option exercise Dispose M No 2.27 32,451 73.66K 685,751
7 Aug 20 TPG Common Stock Sell Dispose S Yes 37.6959 7,686 289.73K 18,716,306
62.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 175 113 +54.9%
Opened positions 71 14 +407.1%
Closed positions 9 19 -52.6%
Increased positions 54 40 +35.0%
Reduced positions 37 35 +5.7%
13F shares
Current Prev Q Change
Total value 4.63B 1.84B +152.1%
Total shares 87.29M 72.65M +20.1%
Total puts 178.2K 94.7K +88.2%
Total calls 323.3K 85.8K +276.8%
Total put/call ratio 0.6 1.1 -50.1%
Largest owners
Shares Value Change
TPG 19.72M $844.25M -7.1%
Capital Research Global Investors 12.01M $514.22M +33.8%
Capital International Investors 7.21M $308.94M +57.6%
Vanguard 5.88M $251.84M +43.5%
BLK BlackRock 5.79M $248.02M +18.1%
N Price T Rowe Associates 3.79M $162.32M +72.0%
Capital World Investors 3.48M $149.06M +16.9%
FMR 2.91M $124.71M -18.4%
STT State Street 2.26M $96.68M +33.3%
VV Manager 1.8M $77M -21.5%
Largest transactions
Shares Bought/sold Change
Capital Research Global Investors 12.01M +3.04M +33.8%
Capital International Investors 7.21M +2.64M +57.6%
Vanguard 5.88M +1.78M +43.5%
N Price T Rowe Associates 3.79M +1.59M +72.0%
TPG 19.72M -1.5M -7.1%
Regents Of The University Of California 1.28M -1.07M -45.6%
Victory Capital Management 1.07M +1.06M +10406.9%
JPM JPMorgan Chase & Co. 1.41M +1.02M +263.5%
BLK BlackRock 5.79M +889.54K +18.1%
Hillhouse Capital Advisors 800K +800K NEW

Financial report summary

?
Risks
  • We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*
  • Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.*
  • Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.*
  • Our business is highly dependent on the success of our lead product candidates. If we are unable to obtain approval for our lead product candidates and effectively commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.*
  • Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*
  • Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.*
  • Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.*
  • We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.*
  • We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.*
  • Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.*
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.*
  • Clinical trials are expensive, time-consuming and difficult to design and implement.*
  • The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.*
  • If we fail to develop additional product candidates, our commercial opportunity may be limited.*
  • Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.*
  • We intend to operate our own manufacturing facility, which will require significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.*
  • We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.
  • A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.*
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.*
  • We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*
  • We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
  • We may not realize the benefits of acquired assets or other strategic transactions.*
  • We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*
  • Our internal computer systems, or those used by our CROs, collaborators or other contractors or consultants, may fail or suffer security breaches.
  • Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.*
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.*
  • Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.
  • European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.*
  • Legal, regulatory, political and economic uncertainty surrounding the exit of the U.K. from the European Union may be a source of instability in international markets, create significant currency fluctuations, adversely affect operations in the U.K. and pose additional risks to our business.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.*
  • We rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*
  • We rely on donors of T cells to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted.*
  • Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.*
  • If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.
  • We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
  • The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.*
  • The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.*
  • We plan to seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.*
  • Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.
  • The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.*
  • If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.
  • Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
  • Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.
  • We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • The lives of our patents may not be sufficient to effectively protect our products and business.
  • We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
  • We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to various compliance initiatives.
  • Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
  • Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to the 2018 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.*
  • We have broad discretion in the use of our cash reserves and may not use them effectively.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
  • If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
Management Discussion
  • Research and development expenses were $47.3 million and $31.8 million for the three months ended June 30, 2020 and 2019, respectively. The increase of $15.5 million was driven primarily by an increase in personnel related costs of $7.3 million, of which $3.2 million was increased stock-based compensation expense, an increase in external costs relating the advancement of our product candidates of $6.9 million, and an increase in building rent and facilities costs of $1.6 million, offset by a decrease in TSA expenses of $0.3 million and a decrease in travel related costs of $0.3 million due to the impact of the COVID-19 pandemic.
  • General and administrative expenses were $15.9 million and $14.2 million for the three months ended June 30, 2020 and 2019, respectively. The net increase of $1.7 million was primarily due to an increase in personnel related costs of $2.4 million, of which $2.1 million was increased stock-based compensation expense, and a $0.8 million increase in building rent and facilities costs, offset by a decrease of $1.5 million in TSA expenses.
  • Interest and other income, net was $2.3 million and $4.6 million for the three months ended June 30, 2020 and 2019, respectively. The decrease of $2.2 million was due to lower interest earned on our cash, cash equivalents and investments.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: battery, Canadian, CMV, division, energy, febrile, gastrointestinal, hemorrhage, hypokalemia, hypotension, installation, insulin, intercompany, NaN, neutropenia, Onyx, photovoltaic, pyrexia, reactivation, Reconciliation, redosing, solar, subsidiary, temporarily, tie, Trust, trustee, underwritten, upper
Removed: accretion, allocated, liquid, owner, persist, recovery